Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 41

1.

Treating village newcomers and travelers for trachoma: Results from ASANTE cluster randomized trial.

West SK, Munoz B, Mkocha H, Dize L, Gaydos CA, Swenor B, Ervin AM, Quinn TC.

PLoS One. 2017 Jun 29;12(6):e0178595. doi: 10.1371/journal.pone.0178595. eCollection 2017.

2.

The Relationship between Active Trachoma and Ocular Chlamydia trachomatis Infection before and after Mass Antibiotic Treatment.

Ramadhani AM, Derrick T, Macleod D, Holland MJ, Burton MJ.

PLoS Negl Trop Dis. 2016 Oct 26;10(10):e0005080. doi: 10.1371/journal.pntd.0005080. eCollection 2016 Oct. Review.

3.

Microbiological Characteristics of Chlamydia trachomatis and Neisseria gonorrhoeae Infections in South African Women.

Dubbink JH, de Waaij DJ, Bos M, van der Eem L, Bébéar C, Mbambazela N, Ouburg S, Peters RP, Morré SA.

J Clin Microbiol. 2016 Jan;54(1):200-3. doi: 10.1128/JCM.02848-15. Epub 2015 Oct 28.

4.
5.

Social Sciences for the Prevention of Blindness.

Goldschmidt P.

Trop Med Health. 2015 Jun;43(2):141-8. doi: 10.2149/tmh.2014-32. Epub 2015 Mar 25. Review.

6.

Chlamydia trachomatis load in population-based screening and STI-clinics: implications for screening policy.

Dirks JA, Wolffs PF, Dukers-Muijrers NH, Brink AA, Speksnijder AG, Hoebe CJ.

PLoS One. 2015 Mar 31;10(3):e0121433. doi: 10.1371/journal.pone.0121433. eCollection 2015.

7.

The limits of medical interventions for the elimination of preventable blindness.

Goldschmidt P, Einterz E.

Trop Med Health. 2014 Mar;42(1):43-52. doi: 10.2149/tmh.2013-26. Epub 2014 Feb 18.

8.

The efficacy of oral azithromycin in clearing ocular chlamydia: mathematical modeling from a community-randomized trachoma trial.

Liu F, Porco TC, Mkocha HA, Muñoz B, Ray KJ, Bailey RL, Lietman TM, West SK.

Epidemics. 2014 Mar;6:10-7. doi: 10.1016/j.epidem.2013.12.001. Epub 2014 Jan 8.

9.

Active trachoma two years after three rounds of azithromycin mass treatment in Cheha District Gurage Zone, Southern Ethiopia.

Admassu F, Bayu S, Bejiga A, Amare B.

BMC Pediatr. 2013 Dec 1;13:199. doi: 10.1186/1471-2431-13-199.

10.

A randomized trial of two coverage targets for mass treatment with azithromycin for trachoma.

West SK, Bailey R, Munoz B, Edwards T, Mkocha H, Gaydos C, Lietman T, Porco T, Mabey D, Quinn TC.

PLoS Negl Trop Dis. 2013 Aug 29;7(8):e2415. doi: 10.1371/journal.pntd.0002415. eCollection 2013.

11.

Assessment of transmission in trachoma programs over time suggests no short-term loss of immunity.

Liu F, Porco TC, Ray KJ, Bailey RL, Mkocha H, Muñoz B, Quinn TC, Lietman TM, West SK.

PLoS Negl Trop Dis. 2013 Jul 11;7(7):e2303. doi: 10.1371/journal.pntd.0002303. Print 2013. Erratum in: PLoS Negl Trop Dis. 2013 Jul;7(7). doi:10.1371/annotation/c64f02de-c1f1-48ee-ac79-06b5a6c7b65a.

12.

Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia.

Harding-Esch EM, Sillah A, Edwards T, Burr SE, Hart JD, Joof H, Laye M, Makalo P, Manjang A, Molina S, Sarr-Sissoho I, Quinn TC, Lietman T, Holland MJ, Mabey D, West SK, Bailey R; Partnership for Rapid Elimination of Trachoma (PRET) study group.

PLoS Negl Trop Dis. 2013 Jun 13;7(6):e2115. doi: 10.1371/journal.pntd.0002115. Print 2013. Erratum in: PLoS Negl Trop Dis. 2013 Jun;7(6). doi:10.1371/annotation/0bae8b34-5ae7-4044-a071-8d88d520a01b.

13.

Will the SAFE strategy be sufficient to eliminate trachoma by 2020? Puzzlements and possible solutions.

Lavett DK, Lansingh VC, Carter MJ, Eckert KA, Silva JC.

ScientificWorldJournal. 2013 May 19;2013:648106. doi: 10.1155/2013/648106. Print 2013. Review.

14.

Development and evaluation of a next-generation digital PCR diagnostic assay for ocular Chlamydia trachomatis infections.

Roberts CH, Last A, Molina-Gonzalez S, Cassama E, Butcher R, Nabicassa M, McCarthy E, Burr SE, Mabey DC, Bailey RL, Holland MJ.

J Clin Microbiol. 2013 Jul;51(7):2195-203. doi: 10.1128/JCM.00622-13. Epub 2013 May 1.

15.

Inhibitory effects of 405 nm irradiation on Chlamydia trachomatis growth and characterization of the ensuing inflammatory response in HeLa cells.

Wasson CJ, Zourelias JL, Aardsma NA, Eells JT, Ganger MT, Schober JM, Skwor TA.

BMC Microbiol. 2012 Aug 15;12:176. doi: 10.1186/1471-2180-12-176.

16.

Trachoma: an update on prevention, diagnosis, and treatment.

Bhosai SJ, Bailey RL, Gaynor BD, Lietman TM.

Curr Opin Ophthalmol. 2012 Jul;23(4):288-95. doi: 10.1097/ICU.0b013e32835438fc. Review.

17.

Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions.

Keenan JD, See CW, Moncada J, Ayele B, Gebre T, Stoller NE, McCulloch CE, Porco TC, Gaynor BD, Emerson PM, Schachter J, Lietman TM.

Invest Ophthalmol Vis Sci. 2012 Jan 25;53(1):235-40. doi: 10.1167/iovs.11-8493.

18.

Association of mass treatment with azithromycin in trachoma-endemic communities with short-term reduced risk of diarrhea in young children.

Coles CL, Seidman JC, Levens J, Mkocha H, Munoz B, West S.

Am J Trop Med Hyg. 2011 Oct;85(4):691-6. doi: 10.4269/ajtmh.2011.11-0046.

19.

Diagnostic accuracy of a prototype point-of-care test for ocular Chlamydia trachomatis under field conditions in The Gambia and Senegal.

Harding-Esch EM, Holland MJ, Schémann JF, Molina S, Sarr I, Andreasen AA, Roberts Ch, Sillah A, Sarr B, Harding EF, Edwards T, Bailey RL, Mabey DC.

PLoS Negl Trop Dis. 2011 Aug;5(8):e1234. doi: 10.1371/journal.pntd.0001234. Epub 2011 Aug 2.

20.

Number of years of annual mass treatment with azithromycin needed to control trachoma in hyper-endemic communities in Tanzania.

West SK, Munoz B, Mkocha H, Gaydos CA, Quinn TC.

J Infect Dis. 2011 Jul 15;204(2):268-73. doi: 10.1093/infdis/jir257.

Supplemental Content

Support Center